SynerFuse

SynerFuse operates at the intersection of spine surgery, implantable medical devices, and neuromodulation. Its core proposition differs from conventional spinal-fusion companies by embedding direct nerve stimulation into the fusion episode rather than treating residual neuropathic pain as a separate downstream problem. The e-TLIF procedure combines transforaminal lumbar interbody fusion with direct nerve stimulation at the same spinal level, while the NeuroFuse System adds an implantable pulse generator, multi-channel lead, mobile programming application, and clinician software. This places SynerFuse in a specialized niche alongside broader spine-device companies and neuromodulation providers, although the available company record does not identify specific named competitors. Its stated hardware-agnostic design may help it work with surgeons’ preferred fusion systems, potentially reducing switching friction relative to a fully integrated implant platform. The company also emphasizes a non-opioid approach to postoperative pain management, aligning with demand for alternatives to chronic opioid use.

SynerFuse’s trajectory shows a transition from early financing and technology development toward clinical validation and commercialization preparation. The company was founded in 2015 and raised $2.64 million in a venture round in May 2019, followed by an $835,000 angel round in December 2019 and a $3.60 million venture round in April 2021. Total disclosed funding is $7.07 million across three rounds, with no later financing publicly identified. Its development program advanced from patient enrollment completion on Oct 17, 2023 to proof-of-concept study completion announced on Mar 3, 2025. The March 2025 agreement with Velentium Medical marked a further inflection point, shifting emphasis toward scaling the e-TLIF procedure. Leadership additions also suggest increasing focus on execution: Michael Park became chief technology officer on Jul 1, 2025, while Susan Alpert holds combined medical and regulatory responsibilities. The company reports a portfolio of issued patents and published applications, supporting protection around its procedural and neuromodulation approach. Growth remains difficult to quantify because employee count is listed only in the 1–10 range, revenue is undisclosed, and no commercial launch or regulatory milestone for the full system is provided.